Integrated Molecular Profiling Improves Subtype Classification and Reveals Inherited Susceptibility in Medulloblastoma: Insights From a Real‐World Cohort
Cancer Medicine · 2026-05 · 15 (5)
DOI: 10.1002/cam4.71783 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 29.04.2026. Verfasst von Jiwei Song und 4 weiteren Autor:innen. Beteiligte Einrichtung: Foshan Sanshui District People's Hospital, Sanshui Hospital, Zhujiang Hospital, Southern Medical University, China. Hauptthemen laut MEDLINE: Medulloblastoma, Genetic Predisposition to Disease, Gene Expression Profiling, Cerebellar Neoplasms. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Medulloblastoma (MB) is a heterogeneous pediatric brain tumor characterized by distinct molecular subtypes. Although genomics and transcriptomics have improved subtype classification and informed targeted therapies, the clinical utility of integrated molecular profiling in real‐world settings remains incompletely defined.
Methods
We conducted a retrospective analysis of 131 patients with MB from a Chinese cohort. All cases underwent both targeted genomic sequencing and NanoString‐based transcriptomic profiling. We evaluated the impact of integrated molecular profiling on diagnostic refinement, identification of germline predisposition, and detection of actionable alterations.
Results
Incorporation of genomic data led to optimized or revised molecular classification in 67.2% of patients. Germline variants in Fanconi anemia pathway genes ( FANCL, FANCC, NBN ) were significantly enriched among patients with Group 3 and Group 4 MB, suggesting a potentially inherited susceptibility component. Furthermore, 52.7% of patients harbored potentially actionable somatic mutations, supporting the feasibility of precision‐targeted therapeutic approaches. Notably, we identified one case of WNT‐subtype MB harboring a homozygous deletion of CDKN2A , which was associated with unusually poor clinical outcome.
Conclusions
Integrated genomic and transcriptomic profiling substantially improves molecular subtyping of MB and reveals inherited risk factors relevant to specific subgroups. Our findings support the implementation of combined molecular diagnostics in routine clinical management of MB and underscore their potential in guiding individualized treatment strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Foshan Sanshui District People's Hospital, Sanshui Hospital, Zhujiang Hospital, Southern Medical University, China.
- State Key Laboratory of Neurology and Oncology Drug Development, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd., Nanjing, China.
ORCID-Profile: Siqi Chen, Ziying Liu
Zitieren
APA
Song, J., Han, T., Chen, S., Chen, D., & Liu, Z. (2026). Integrated Molecular Profiling Improves Subtype Classification and Reveals Inherited Susceptibility in Medulloblastoma: Insights From a Real‐World Cohort. Cancer Medicine, 15(5). https://doi.org/10.1002/cam4.71783
Vancouver
Song J, Han T, Chen S, Chen D, Liu Z. Integrated Molecular Profiling Improves Subtype Classification and Reveals Inherited Susceptibility in Medulloblastoma: Insights From a Real‐World Cohort. Cancer Medicine. 2026;15(5). doi:10.1002/cam4.71783
BibTeX
@article{Song2026,
author = {Song, Jiwei and Han, Tiantian and Chen, Siqi and Chen, Dongsheng and Liu, Ziying},
title = {Integrated Molecular Profiling Improves Subtype Classification and Reveals Inherited Susceptibility in Medulloblastoma: Insights From a Real‐World Cohort},
journal = {Cancer Medicine},
year = {2026},
volume = {15},
number = {5},
doi = {10.1002/cam4.71783}
}
EUVIMED